# OrsoBio

**Canonical:** https://apis.io/providers/orsobio/  
**Website:** https://orsobio.com/  
**APIs profiled:** 0

OrsoBio is a privately held, clinical-stage biopharmaceutical company founded in 2021 and headquartered in Palo Alto, California, developing first-in-class oral therapies that restore energy homeostasis in patients living with severe metabolic disorders — obesity, type 2 diabetes, severe dyslipidemias, lipodystrophies and MASH. The name is drawn from the metabolic adaptability of bears ("orso" in Italian). Its pipeline is led by three mitochondrial protonophores — TLC-6740, TLC-1180 and TLC-1235 — intended to increase energy expenditure and improve metabolic and cardiovascular health, alongside an LXR inverse agonist (TLC-2716) for severe hypertriglyceridemia and MASH, an ACC2 inhibitor (TLC-3595) for insulin sensitivity in type 2 diabetes, and an ACMSD inhibitor to augment NAD+ biosynthesis in metabolic and inflammatory liver and kidney disorders. The company closed an oversubscribed $67 million Series B in September 2024, co-led by Ascenta Capital and Woodline Partners with participation from Samsara BioCapital, Enavate Sciences and Longitude Capital. OrsoBio publishes a corporate site covering its science, pipeline, team, board, publications, events and press releases, but runs no developer program: no API documentation, no SDKs, no developer portal, no GitHub organisation and no machine-readable API contract of any kind. The only machine-readable surface on orsobio.com is the site's own WordPress CMS route index, which the site's robots.txt explicitly disallows at /wp-json/ and which is therefore not harvested or catalogued here.

## Kin Score — 8.9 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 8.9).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 2.2 |
| Commercial Clarity | 10.5 |

Regulatory layer — **Health**: 12.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Orsobio Domain Security** — TLSv1.3 · DNSSEC

## Tags

Company, Biotechnology, Pharmaceuticals, Life Sciences, Metabolic Disease, Obesity, Clinical Trials, Drug Development, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/orsobio/). Scores are computed from the provider's own public artifacts under a published rubric.